Clinical profile of acute pancreatitis following treatment with protease inhibitors: a real-world analysis of post-marketing surveillance data

References

• Crum NF, Riffenburgh RH, Wegner S, et al. Comparisons of causes of death and mortality rates among HIV-infected persons. I Acquir Immune Defic Syndr. 2006;41(2):194–200.
   PubMed Web of Science ®Google Scholar
• De Leuw P, Stephan C. Protease inhibitor therapy for hepatitis C virus-infection. Expert Opin Pharmacother. 2018 Apr;19(6):577–587.
   PubMed Web of Science ®Google Scholar
• Ghosh AK, Osswald HL, Prato G. Recent progress in the development of HIV-1 protease inhibitors for the treatment of HIV/AIDS. J Med Chem. 2016 Jun 9;59(11):5172–5208.
   PubMed Web of Science ®Google Scholar
• Hughes PJ, Cretton-Scott E, Teague A, et al. Protease inhibitors for patients with HIV-1 infection: a comparative overview. P T. 2011 Jun;36(6):332–345.
   PubMedGoogle Scholar
• Palella FJ Jr., Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV outpatient study investigators. N Engl J Med. 1998 Mar 26;338(13):853–860.
   PubMed Web of Science ®Google Scholar
• Carnovale C, Pozzi M, Dassano A, et al. The impact of a successful treatment of hepatitis C virus on glyco-metabolic control in diabetic patients: a systematic review and meta-analysis. Acta Diabetol. 2019 Mar;56(3):341–354.
   PubMed Web of Science ®Google Scholar
• Chu CM, Cheng VC, Hung IF, et al. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax. 2004 Mar;59(3):252–256.
   PubMed Web of Science ®Google Scholar
• Sheahan TP, Sims AC, Leist SR, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun. 2020 Jan 10;11(1):222.
   PubMed Web of Science ®Google Scholar
• Kim UJ, Won EJ, Kee SJ, et al. Combination therapy with lopinavir/ritonavir, ribavirin and interferon-alpha for middle east respiratory syndrome. Antivir Ther. 2016;21(5):455–459.
   PubMed Web of Science ®Google Scholar
• Solerte SB, D’Addio F, Trevisan R, et al. Sitagliptin treatment at the time of hospitalization was associated with reduced mortality in patients with type 2 diabetes and COVID-19: a multicenter, case-control, retrospective, observational study. Diabetes Care. 2020 Dec;43(12):2999–3006.
   PubMed Web of Science ®Google Scholar
• Walmsley S. Protease inhibitor-based regimens for HIV therapy: safety and efficacy. JAIDS J Acquir Immune Defic Syndr. 2007 Jun 1;45(Suppl 1):SS5–31.
   Web of Science ®Google Scholar
• Liu J, Shah SK, Basu-Ray I, et al. QT prolongation in HIV-positive patients: review article. Indian Heart J. 2019 Nov-Dec;71(6):434–439.
   PubMedGoogle Scholar
• Calza L, Manfredi R, Farneti B, et al. Incidence of hyperlipidaemia in a cohort of 212 HIV-infected patients receiving a protease inhibitor-based antiretroviral therapy. Int J Antimicrob Agents. 2003 Jul;22(1):54–59.
   PubMed Web of Science ®Google Scholar
• Warriner AH, Burkholder GA, Overton ET. HIV-related metabolic comorbidities in the current ART era. Infect Dis Clin North Am. 2014 Sep;28(3):457–476.
   PubMed Web of Science ®Google Scholar
• Montessori V, Press N, Harris M, et al. Adverse effects of antiretroviral therapy for HIV infection. CMAJ : Canadian Med Assoc J = Journal De l’Association Medicale Canadienne. 2004 Jan 20;170(2):229–238.
   PubMed Web of Science ®Google Scholar
• Safrin S, Grunfeld C. Fat distribution and metabolic changes in patients with HIV infection. AIDS. 1999 Dec 24;13(18):2493–2505.
   PubMed Web of Science ®Google Scholar
• Oliveira NM, Ferreira FA, Yonamine RY, et al. Antiretroviral drugs and acute pancreatitis in HIV/AIDS patients: is there any association? A literature review. Einstein (Sao Paulo). 2014 Jan-Mar;12(1):112–119.
   PubMedGoogle Scholar
• Croxtall JD, Perry CM. Lopinavir/Ritonavir: a review of its use in the management of HIV-1 infection. Drugs. 2010 Oct 1;70(14):1885–1915.
   PubMed Web of Science ®Google Scholar
• Reisler RB, Murphy RL, Redfield RR, et al. Incidence of pancreatitis in HIV-1-infected individuals enrolled in 20 adult AIDS clinical trials group studies: lessons learned. J Acquir Immune Defic Syndr. 2005 Jun 1;39(2):159–166.
   PubMed Web of Science ®Google Scholar
• Bush ZM, Kosmiski LA. Acute pancreatitis in HIV-infected patients: are etiologies changing since the introduction of protease inhibitor therapy? Pancreas. 2003 Jul;27(1):e1–5.
   PubMed Web of Science ®Google Scholar
• Manfredi R, Calza L, Chiodo F. A case-control study of HIV-associated pancreatic abnormalities during HAART era. Focus on emerging risk factors and specific management. Eur J Med Res. 2004 Dec 22; 9(12):537–544.
   PubMed Web of Science ®Google Scholar
• Manfredi R, Calza L. HIV infection and the pancreas: risk factors and potential management guidelines. Int J STD AIDS. 2008 Feb;19(2):99–105.
   PubMed Web of Science ®Google Scholar
• Mirete G, Masia M, Gutierrez F, et al. Acute pancreatitis as a complication of ritonavir therapy in a patient with AIDS. Eur J Clin Microbiol Infect Dis. 1998 Nov;17(11):810–811.
   PubMed Web of Science ®Google Scholar
• Perry RC, Cushing HE, Deeg MA, et al. Ritonavir, triglycerides, and pancreatitis. Clin Infect Dis. 1999 Jan;28(1):161–162.
   PubMed Web of Science ®Google Scholar
• Di Martino V, Ezenfis J, Benhamou Y, et al. Severe acute pancreatitis related to the use of nelfinavir in HIV infection: report of a case with positive rechallenge. AIDS. 1999 Jul 30;13(11):1421–1423.
   PubMed Web of Science ®Google Scholar
• Van Puijenbroek EP, Bate A, Leufkens HG, et al. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf. 2002 Jan-Feb;11(1):3–10.
   PubMed Web of Science ®Google Scholar
• Szumilas M. Explaining odds ratios. J Canadian Acad Child Adolescent Psych = J de l’Academie canadienne de psychiatrie de l’enfant et de l’adolescent 2010 Aug;19(3):227–229.
   PubMed Web of Science ®Google Scholar
• Ooba N, Kubota K. Selected control events and reporting odds ratio in signal detection methodology. Pharmacoepidemiol Drug Saf. 2010 Nov;19(11):1159–1165.
   PubMed Web of Science ®Google Scholar
• Evans SJ, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf. 2001 Oct-Nov;10(6):483–486.
   PubMed Web of Science ®Google Scholar
• Hauben M, Madigan D, Gerrits CM, et al. The role of data mining in pharmacovigilance. Expert Opin Drug Saf. 2005 Sep;4(5):929–948.
   PubMedGoogle Scholar
• Norén GN, Bate A, Orre R, et al. Extending the methods used to screen the WHO drug safety database towards analysis of complex associations and improved accuracy for rare events. Stat Med. 2006 Nov 15;25(21):3740–3757.
   PubMed Web of Science ®Google Scholar
• Hauben M. A brief primer on automated signal detection. Ann Pharmacother. 2003 Jul-Aug;37(7–8):1117–1123.
   PubMed Web of Science ®Google Scholar
• Louis TA, Shen W. [Bayesian data mining in large frequency tables, with an application to the fda spontaneous reporting system]: discussion. Am Stat. 1999;53(3):196.
   Google Scholar
• Szarfman A, Machado SG, O’Neill RT. Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA’s spontaneous reports database. Drug Saf. 2002;25(6):381–392.
   PubMed Web of Science ®Google Scholar
• Moore RD, Keruly JC, Chaisson RE. Incidence of pancreatitis in HIV-infected patients receiving nucleoside reverse transcriptase inhibitor drugs. AIDS. 2001 Mar 30;15(5):617–620.
   PubMed Web of Science ®Google Scholar
• Dragovic G, Milic N, Jevtovic DJ. Incidence of acute pancreatitis and nucleoside reverse transcriptase inhibitors usage. Int J STD AIDS. 2005 Jun;16(6):427–429.
   PubMed Web of Science ®Google Scholar
• Johnson AS, Song R, Hall HI. Estimated HIV incidence, prevalence, and undiagnosed infections in US States and Washington, DC, 2010–2014. J Acquired Immune Deficiency Syndromes. 1999;2017:116.
   Google Scholar
• Guo JJ, Jang R, Louder A, et al. Acute pancreatitis associated with different combination therapies in patients infected with human immunodeficiency virus. Pharmacotherapy. 2005 Aug;25(8):1044–1054.
   PubMed Web of Science ®Google Scholar
• Riedel DJ, Gebo KA, Moore RD, et al. A ten-year analysis of the incidence and risk factors for acute pancreatitis requiring hospitalization in an urban HIV clinical cohort. AIDS Patient Care STDS. 2008 Feb;22(2):113–121.
   PubMed Web of Science ®Google Scholar
• Friedewald VE, Ballantyne CM, Bays HE, et al. The editor’s roundtable: hypertriglyceridemia. Am J Cardiol. 2013 Oct 15;112(8):1133–1141.
   PubMed Web of Science ®Google Scholar
• Lederle FA, Bloomfield HE. Drug treatment of asymptomatic hypertriglyceridemia to prevent pancreatitis: where is the evidence? Ann Intern Med. 2012 Nov 6;157(9):662–664.
   PubMed Web of Science ®Google Scholar
• Sun HY, Chang SY, Sheng WH, et al. Incidence of acute pancreatitis in human immunodeficiency virus-positive patients with hypertriglyceridemia: is it really high? Pancreas. 2012 Mar;41(2):283–289.
   PubMed Web of Science ®Google Scholar
• Marot JC, Jonckheere S, Munyentwali H, et al. Tigecycline-induced acute pancreatitis: about two cases and review of the literature. Acta Clin Belg. 2012 May-Jun;67(3):229–232.
   PubMed Web of Science ®Google Scholar
• Tsiodras S, Mantzoros C, Hammer S, et al. Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: a 5-year cohort study. Arch Internal Med. 2000 Jul 10;160(13):2050–2056.
   PubMed Web of Science ®Google Scholar
• Salami AK, Akande AA, Olokoba AB. Serum lipids and glucose abnormalities in HIV/AIDS patients on antiretroviral therapies. West Afr J Med. 2009 Jan;28(1):10–15.
   PubMedGoogle Scholar
• Lugassy DM, Farmer BM, Nelson LS. Metabolic and hepatobiliary side effects of antiretroviral therapy (ART). Emerg Med Clin North Am. 2010 May;28(2):409–419.
   PubMed Web of Science ®Google Scholar
• Golomb BA, Verden A, Messner AK, et al. Amyotrophic lateral sclerosis associated with statin use: a disproportionality analysis of the FDA’s adverse event reporting system. Drug saf. 2018 Apr;41(4):403–413.
   PubMed Web of Science ®Google Scholar
• Shen J, Yang J, Zhao B. A survey of the FDA’s adverse event reporting system database concerning urogenital tract infections and sodium glucose cotransporter‐2Inhibitor use. Diabetes Ther. 2019 Jun;10(3):1043–1050.
   Google Scholar
• Fan Q, Hu Y, Yang C, et al. Myocarditis following the use of different immune checkpoint inhibitor regimens: a real-world analysis of post-marketing surveillance data. Int Immunopharmacol. 2019;76:105866.
   PubMed Web of Science ®Google Scholar